Skip to main content
. 2015 Aug 5;12:24. doi: 10.1186/s12981-015-0065-8

Table 1.

Comparison of baseline and follow-up characteristics of female participants

Baseline median (IQR), n = 84 Follow-up median (IQR), n = 77
Age 33.5 (30.0–40.0) 40.1 (35.7–45.4)
Current CD4 count 372 (261–471) 564 (427–774)
Time on ART (months) 16.0 (10.0–26.0) 82.4 (73.8–94.1)
n (%) n (%)
No schooling 5 (4.8)
Primary School 14 (13.6)
Secondary School 83 (80.6)
Tertiary 1 (1.0)
1st line ART 84 (100) 65 (84.4)
2nd line ART 0 (0) 12 (15.6)
Stavudine 76 (90.5) 30 (39.0)
Lamivudine 84 (100) 77 (100)
Zidovudine 8 (9.5) 29 (37.7)
Tenofovir 0 (0.0) 18 (23.4)
Lopinavir 0 (0.0) 12 (15.6)
Efavirenz 41 (48.8) 36 (46.8)
Nevirapine 43 (51.2) 29 (37.7)